Misplaced Pages

Amlodipine/benazepril

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Antihypertensive medication

Pharmaceutical compound
Amlodipine/benazepril
Combination of
AmlodipineCalcium channel blocker
BenazeprilACE inhibitor
Clinical data
Trade namesLotrel
AHFS/Drugs.comProfessional Drug Facts
License data
Routes of
administration
By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
KEGG
CompTox Dashboard (EPA)
  (what is this?)  (verify)

Amlodipine/benazepril, sold under the brand name Lotrel among others, is a fixed-dose combination medication used to treat high blood pressure. It is a combination of amlodipine, as the besilate, a calcium channel blocker, and benazepril, an angiotensin converting enzyme inhibitor. It may be used if a single agent is not sufficient. It is taken by mouth.

Common side effects include cough, dizziness, and swelling. Serious side effects may include angioedema, myocardial infarction, high blood potassium, liver problems, and low blood pressure. Use in pregnancy is not recommended. Amlodipine works by increasing the size of arteries while benazepril works by decreasing renin-angiotensin-aldosterone system activity.

The combination was approved for medical use in the United States in 1995. It is available as a generic medication. In 2022, it was the 170th most commonly prescribed medication in the United States, with more than 3 million prescriptions.

Medical uses

It is used to treat high blood pressure. It is not a first-line treatment.

References

  1. ^ "Lotrel- amlodipine besylate and benazepril hydrochloride capsule". DailyMed. U.S. National Library of Medicine. Retrieved 20 June 2021.
  2. Cerner Multum. "Amlodipine and benazepril Uses, Side Effects & Warnings". Drugs.com. Retrieved 10 March 2019.
  3. Bope ET, Kellerman RD (2016). Conn's Current Therapy 2017 E-Book. Elsevier Health Sciences. p. 124. ISBN 978-0-323-44335-7.
  4. "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  5. "Amlodipine; Benazepril Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
  6. Faulkner MA, Hilleman DE (January 2001). "Amlodipine/benazepril: fixed dose combination therapy for hypertension". Expert Opinion on Pharmacotherapy. 2 (1): 165–178. doi:10.1517/14656566.2.1.165. PMID 11336577. S2CID 23021242.
Antihypertensive drugs acting on the renin–angiotensin system (C09)
ACE inhibitors
("-pril")
AIIRAs
("-sartan")
Renin inhibitors
("-kiren")
Dual ACE/NEP inhibitors
Neprilysin inhibitors
Other
Ion channel modulators
Calcium
VDCCsTooltip Voltage-dependent calcium channels
Blockers
Activators
Potassium
VGKCsTooltip Voltage-gated potassium channels
Blockers
Activators
IRKsTooltip Inwardly rectifying potassium channel
Blockers
Activators
KCaTooltip Calcium-activated potassium channel
Blockers
Activators
K2PsTooltip Tandem pore domain potassium channel
Blockers
Activators
Sodium
VGSCsTooltip Voltage-gated sodium channels
Blockers
Activators
ENaCTooltip Epithelial sodium channel
Blockers
Activators
ASICsTooltip Acid-sensing ion channel
Blockers
Chloride
CaCCsTooltip Calcium-activated chloride channel
Blockers
Activators
CFTRTooltip Cystic fibrosis transmembrane conductance regulator
Blockers
Activators
Unsorted
Blockers
Others
TRPsTooltip Transient receptor potential channels
LGICsTooltip Ligand gated ion channels
See also: Receptor/signaling modulatorsTransient receptor potential channel modulators
Portal:


Stub icon

This drug article relating to the cardiovascular system is a stub. You can help Misplaced Pages by expanding it.

Categories: